GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease (“CVD”). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company’s products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.
GENI
Stifel Nicolaus Europe Limited
Stifel Nicolaus Europe Limited